SG11202009866XA - Compositions and methods for cancer or neoplasia assessment - Google Patents

Compositions and methods for cancer or neoplasia assessment

Info

Publication number
SG11202009866XA
SG11202009866XA SG11202009866XA SG11202009866XA SG11202009866XA SG 11202009866X A SG11202009866X A SG 11202009866XA SG 11202009866X A SG11202009866X A SG 11202009866XA SG 11202009866X A SG11202009866X A SG 11202009866XA SG 11202009866X A SG11202009866X A SG 11202009866XA
Authority
SG
Singapore
Prior art keywords
neoplasia
assessment
cancer
compositions
methods
Prior art date
Application number
SG11202009866XA
Other languages
English (en)
Inventor
Athurva J Gore
Jeffrey A Gole
Rui Liu
Original Assignee
Singlera Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Singlera Genomics Inc filed Critical Singlera Genomics Inc
Publication of SG11202009866XA publication Critical patent/SG11202009866XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2531/00—Reactions of nucleic acids characterised by
    • C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
    • C12Q2531/113—PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
SG11202009866XA 2018-04-12 2019-04-08 Compositions and methods for cancer or neoplasia assessment SG11202009866XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862656820P 2018-04-12 2018-04-12
PCT/US2019/026395 WO2019199696A1 (en) 2018-04-12 2019-04-08 Compositions and methods for cancer or neoplasia assessment

Publications (1)

Publication Number Publication Date
SG11202009866XA true SG11202009866XA (en) 2020-11-27

Family

ID=68163272

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202009866XA SG11202009866XA (en) 2018-04-12 2019-04-08 Compositions and methods for cancer or neoplasia assessment

Country Status (10)

Country Link
US (1) US12686889B2 (cg-RX-API-DMAC7.html)
EP (1) EP3775290A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021520809A (cg-RX-API-DMAC7.html)
KR (1) KR20210003795A (cg-RX-API-DMAC7.html)
CN (1) CN112352057A (cg-RX-API-DMAC7.html)
AU (1) AU2019253569A1 (cg-RX-API-DMAC7.html)
CA (1) CA3096668A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202009866XA (cg-RX-API-DMAC7.html)
TW (1) TW202012638A (cg-RX-API-DMAC7.html)
WO (1) WO2019199696A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111989407B (zh) 2018-03-13 2024-10-29 格里尔公司 异常的片段检测及分类
CA3302676A1 (en) 2018-04-02 2026-05-13 Grail, Inc. Methylation markers and targeted methylation probe panels
EP3856903A4 (en) 2018-09-27 2022-07-27 Grail, LLC METHYLATION MARKER AND TARGETED METHYLATION PROBE PANEL
EP3899953A1 (en) 2018-12-21 2021-10-27 Grail, Inc. Source of origin deconvolution based on methylation fragments in cell-free-dna samples
CA3127329A1 (en) 2019-01-24 2020-07-30 Mayo Foundation For Medical Education And Research Detecting endometrial cancer
US11795495B1 (en) * 2019-10-02 2023-10-24 FOXO Labs Inc. Machine learned epigenetic status estimator
JP7799607B2 (ja) * 2019-10-31 2026-01-15 マヨ ファウンデーション フォア メディカル エデュケーション アンド リサーチ 卵巣癌の検出
CN111833965B (zh) * 2019-11-08 2024-06-04 中国科学院北京基因组研究所(国家生物信息中心) 一种尿沉渣基因组dna的分类方法、装置和用途
EP4067488A4 (en) * 2019-11-27 2024-10-30 Keio University METHOD FOR IDENTIFYING UPPER EXCRETORY TRACT UROTHELIAL CARCINOMA
JP7801235B2 (ja) * 2020-03-20 2026-01-16 シングレラ・ヘルス・テクノロジーズ(シャンハイ)・リミテッド 結腸直腸新生物をスクリーニングするための方法およびキット
CA3222729A1 (en) * 2021-06-18 2022-12-22 Rui Liu Substance and method for tumor assessment
CN115985486B (zh) * 2021-10-13 2026-05-01 江苏鹍远生物科技股份有限公司 一种基于机器学习的胰腺癌诊断方法
EP4419714A4 (en) * 2021-11-23 2025-02-26 Pleno, Inc. CODED DOSAGES
TW202328459A (zh) * 2021-12-20 2023-07-16 大陸商江蘇鵾遠生物技術有限公司 一種腫瘤檢測方法及應用
CN114959038B (zh) * 2022-06-13 2024-12-17 湖南宏雅基因技术有限公司 一种hoxa9基因甲基化检测试剂及其应用
CN117660633A (zh) * 2022-08-04 2024-03-08 江苏鹍远生物科技股份有限公司 标志物在诊断乳腺癌或预测乳腺癌风险中的用途
CN117766028B (zh) * 2022-09-16 2025-03-11 深圳吉因加医学检验实验室 一种基于甲基化差异预测样本来源的方法及装置
JP2025537955A (ja) 2022-11-29 2025-11-20 ジーシー ゲノム コーポレーション 食道癌及び胃癌診断用dnaメチル化マーカー及びその用途
WO2024137858A2 (en) * 2022-12-22 2024-06-27 Singlera Genomics Inc. Methods and compositions for assessing colorectal cancer
EP4669776A1 (en) * 2023-02-22 2025-12-31 University of Southern California EARLY PAN-CANCER DETECTION AND CFDNA METHYLATION IN THE CONTEXT OF MINIMAL RESIDUAL DISEASE
WO2025203031A2 (en) * 2024-03-26 2025-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of cancer detection by discordant methylation in cfdna

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060134643A1 (en) 2000-06-19 2006-06-22 Kurt Berlin Bisulfite conversion of DNA
DK1423528T3 (da) * 2000-09-01 2008-05-13 Epigenomics Ag Fremgangsmåde til bestemmelse af methyleringsgraden af bestemte cytosiner i genomisk DNA i sekvenskonteksten 5-CPG-3
US7620386B2 (en) 2006-06-08 2009-11-17 At&T Intellectual Property I, Lp Establishing a collaborative domain among communication terminals responsive to authentication
EP2474628B1 (en) * 2007-02-21 2015-10-28 Oslo Universitetssykehus HF New markers for cancer
US20100297067A1 (en) * 2007-05-14 2010-11-25 The Johns Hopkins University Methylation markers for prostate cancer and methods of use
US7843254B2 (en) * 2007-10-31 2010-11-30 Texas Instruments Incorporated Methods and apparatus to produce fully isolated NPN-based bandgap reference
WO2009108917A2 (en) 2008-02-29 2009-09-03 Oncomethylome Sciences, S.A. Markers for improved detection of breast cancer
AU2010213510B2 (en) 2009-02-16 2014-05-01 Epicentre Technologies Corporation Template-independent ligation of single-stranded DNA
WO2011112845A2 (en) * 2010-03-11 2011-09-15 Board Of Regents, The University Of Texas System Methods and compositions related to a multi-methylation assay to predict patient outcome
EP2850212B1 (en) * 2012-05-18 2020-01-01 Clinical Genomics Pty. Ltd. A method of screening for colorectal cancer
HK1217971A1 (zh) 2013-02-21 2017-01-27 Toma Biosciences Inc 用於核酸分析的方法、組合物和試劑盒
US9365902B2 (en) 2013-03-15 2016-06-14 Abbott Molecular Inc. Detection of bisulfite converted nucleotide sequences
EP2886659A1 (en) * 2013-12-20 2015-06-24 AIT Austrian Institute of Technology GmbH Gene methylation based colorectal cancer diagnosis
EP3224377B1 (en) * 2014-11-25 2020-01-01 AIT Austrian Institute of Technology GmbH Diagnosis of lung cancer
US9984201B2 (en) 2015-01-18 2018-05-29 Youhealth Biotech, Limited Method and system for determining cancer status
EP3262191B2 (en) * 2015-02-24 2023-06-14 Zymo Research Corporation Assays to determine dna methylation and dna methylation markers of cancer
WO2017048932A1 (en) 2015-09-17 2017-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cancer detection methods
AU2017260630B2 (en) * 2016-05-05 2023-07-13 Exact Sciences Corporation Detection of lung neoplasia by analysis of methylated DNA
KR102601593B1 (ko) 2017-04-19 2023-11-13 싱글레라 제노믹스, 인코포레이티드 라이브러리 제작 및 서열 분석을 위한 조성물 및 방법
US20200048697A1 (en) 2017-04-19 2020-02-13 Singlera Genomics, Inc. Compositions and methods for detection of genomic variance and DNA methylation status
JP7801235B2 (ja) 2020-03-20 2026-01-16 シングレラ・ヘルス・テクノロジーズ(シャンハイ)・リミテッド 結腸直腸新生物をスクリーニングするための方法およびキット

Also Published As

Publication number Publication date
TW202012638A (zh) 2020-04-01
US20210388445A1 (en) 2021-12-16
US12686889B2 (en) 2026-07-21
JP2021520809A (ja) 2021-08-26
CA3096668A1 (en) 2019-10-17
AU2019253569A1 (en) 2020-10-29
WO2019199696A1 (en) 2019-10-17
CN112352057A (zh) 2021-02-09
KR20210003795A (ko) 2021-01-12
EP3775290A4 (en) 2021-12-29
EP3775290A1 (en) 2021-02-17

Similar Documents

Publication Publication Date Title
EP3775290A4 (en) Compositions and methods for cancer or neoplasia assessment
ZA202006627B (en) Methods and compositions for treating cancer
IL277079A (en) Cartirin preparations and methods of use
ZA202003849B (en) Vcar compositions and methods for use
IL280134A (en) Anti-CD112R preparations and methods
IL276808A (en) Preparations and methods for the treatment of cancer
IL266053A (en) Preparations and methods for the treatment of ezh2-mediated cancer
SG11202106612QA (en) Improved antibody-oligonucleotide conjugate
IL274837A (en) Methods and preparations for the treatment of cancer
ZA202001572B (en) Risk determination for neoplasia and cancer
IL271680A (en) Compositions and methods for inhibiting expression of HMGB1
IL325803A (en) Compositions and methods for treating cancer
SG11202012435UA (en) Compositions and methods for treating cancer
IL274524A (en) Preparations and methods for aquaculture
SG11202104448WA (en) Compositions and methods
SG11202106295WA (en) Compositions and methods for cancer therapy
GB201817444D0 (en) Methods and compositions
SG11202106857VA (en) Compositions and methods for inhibiting hmgb1 expression
EP3630090A4 (en) CANCER POLYTHERAPY USING PLANT COMPOSITIONS AND ENZALUTAMIDE
IL268268B (en) Methods and compounds for the evaluation of cancerous tumors
IL282948B2 (en) Cancer treatment preparations and methods
EP3714043A4 (en) Compositions and methods for treating cancer
IL272782A (en) Preparations and methods for the treatment of cancer
GB201819987D0 (en) Methods and compositions
SG11202000724XA (en) Methods and compositions for the treatment of cancer